慧聰集團(02280.HK):附屬惠州棉聯獲大亞灣科創1.5億元入股
格隆匯8月9日丨慧聰集團(02280.HK)宣佈,於2021年8月9日,公司及集團若干成員公司與惠州大亞灣科創(作為投資者)及其餘訂約各方訂立投資協議。根據投資協議,(其中包括)惠州大亞灣科創有條件同意向惠州棉聯作出人民幣1.5億元現金投資。
於完成後,惠州棉聯將由北京慧聰科技、天津慧聰及惠州大亞灣科創分別擁有5.01298%、30.688%及30%權益,而北京慧聰科技及天津慧聰均為集團附屬公司。於完成後,惠州棉聯及上海棉聯將仍為公司的附屬公司,其財務業績將繼續入賬及併入集團的財務業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.